Senior management changes at Merck & Co
This article was originally published in Scrip
Executive Summary
Merck & Co has announced changes to its senior management team: president of the global human health worldwide sales and marketing division Kenneth Frazier has been elected as company president, effective 1 May. He will report to the Merck's current chairman, CEO and president, Richard Clark, who will continue to lead the company as chairman and CEO. Adam Schechter, president of the company's pharmaceutical business in the US, has been elected to succeed Mr Frazier as president of global human health.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.